Je was op zoek naar: osimertinib (Maltees - Engels)

tagrisso 40 mg pilloli osimertinib
tagrisso 40 mg tablets osimertinib

fih is-sustanza attiva osimertinib.
it contains the active substance osimertinib.

tagrisso 40 mg pilloli miksijin b’rita osimertinib
tagrisso 40 mg film-coated tablets osimertinib

l-effetti ta' osimertinib fuq p-gp u bcrp
effects of osimertinib on p-gp and bcrp

kull pillola fiha 40 mg osimertinib (bħala mesylate).
each tablet contains 40 mg osimertinib (as mesylate).

is-sustanza attiva hija osimertinib (bħala mesylate).
the active substance is osimertinib (as mesylate).

osimertinib jista' jżid l- espożizzjoni tas-sottostrati ta' bcrp.
osimertinib may increase the exposure of bcrp substrates.

osimertinib ma kkawżax ħsara ġenetika f'assaġġi in vitro u in vivo.
osimertinib did not cause genetic damage in in vitro and in vivo assays.

effett ta' sustanzi attivi li jnaqqsu l-aċidu gastriku fuq osimertinib
effect of gastric acid reducing active substances on osimertinib

studji in vitro jindikaw li osimertinib huwa prinċipalment metabolizzat minn cyp3a4, u cyp3a5.
in vitro studies indicate that osimertinib is metabolized predominantly by cyp3a4, and cyp3a5.

indutturi qawwija ta' cyp3a4 jistgħu jnaqqsu l-espożizzjoni ta' osimertinib.
strong cyp3a4 inducers can decrease the exposure of osimertinib.

osimertinib huwa inibitur ta' tyrosine kinase (tyrosine kinase inhibitor, tki).
osimertinib is a tyrosine kinase inhibitor (tki).

abbażi ta' studji in vitro, osimertinib huwa inibitur kompetittiv tat-trasportaturi ta' bcrp.
based on in vitro studies, osimertinib is a competitive inhibitor of bcrp transporters.

għalhekk, mhuwiex probabbli li l-inibituri ta' cyp3a4 jaffettwaw l-espożizzjoni għal osimertinib.
therefore, cyp3a4 inhibitors are not likely to affect the exposure of osimertinib.

ecgs serjali nġabru wara doża unika u fi stat fiss biex jiġi evalwat l-effett ta' osimertinib fl-intervalli qtc.
serial ecgs were collected following a single dose and at steady-state to evaluate the effect of osimertinib on qtc intervals.

abbażi ta' dejta in vitro, osimertinib huwa inibitur ta' bcrp. (ara sezzjoni 4.5).
based on in vitro data, osimertinib is an inhibitor of bcrp and

fi studju modifikat dwar l-iżvilupp embrijofetali fil-firien, osimertinib ikkawża embrijoletalità meta ngħata lil firien tqal qabel impjantazzjoni embrijonika.
in a modified embryofoetal development study in the rat, osimertinib caused embryolethality when administered to pregnant rats prior to embryonic implantation.

in vitro, osimertinib ma jinibixxix p-glycoprotein, oat1, oat3, oatp1b1, oatp1b3 u mate2k f'konċentrazzjonijiet klinikament relevanti.
in vitro, osimertinib does not inhibit oat1, oat3, oatp1b1, oatp1b3 and mate2k at clinically relevant concentrations.

abbażi ta' studji in vitro, osimertinib mhuwiex inibitur ta' ugt1a1 u ugt2b7 f'konċentrazzjonijiet klinikament rilevanti fil-fwied.
based on in vitro studies, osimertinib is not an inhibitor of ugt1a1 and ugt2b7 at clinically relevant concentrations hepatically.

fi studji kliniku farmakokinetiku, l-għoti flimkien ta' omeprazole ma rriżultax f'tibdil klinikament rilevanti fl-espożizzjonijiet għal osimertinib.
in a clinical pharmacokinetic study, co-administration of omeprazole did not result in clinically relevant changes in osimertinib exposures.